- Report
- January 2022
- 209 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- January 2022
- 294 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- April 2019
- 850 Pages
Global
From €3976EUR$4,499USD£3,503GBP
- Report
- September 2024
- 174 Pages
Global
From €2050EUR$2,485USD£1,869GBP
- Report
- September 2020
- 240 Pages
Global
From €4329EUR$4,899USD£3,814GBP
- Report
- May 2024
- 224 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- April 2022
- 481 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- March 2022
- 220 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- January 2022
- 242 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- April 2021
- 302 Pages
Global
From €4241EUR$4,799USD£3,736GBP
- Report
- August 2019
- 519 Pages
Global
From €3976EUR$4,499USD£3,503GBP
- Report
- January 2019
- 230 Pages
Global
From €3534EUR$3,999USD£3,113GBP
- Report
- June 2024
- 299 Pages
Global
From €5110EUR$5,986USD£4,350GBP
- Report
- May 2024
- 391 Pages
Global
From €5110EUR$5,986USD£4,350GBP
- Report
- February 2024
- 270 Pages
Global
From €5110EUR$5,986USD£4,350GBP
- Report
- December 2023
- 261 Pages
Global
From €4641EUR$5,435USD£3,950GBP
- Report
- June 2023
- 308 Pages
Global
From €4641EUR$5,435USD£3,950GBP
- Report
- March 2023
- 232 Pages
Global
From €4641EUR$5,435USD£3,950GBP
- Report
- January 2023
- 281 Pages
Global
From €4641EUR$5,435USD£3,950GBP
- Report
- June 2024
- 569 Pages
Global
From €1292EUR$1,514USD£1,100GBP

The biologic market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs. Biologic drugs are made from living organisms, such as proteins, nucleic acids, and cells, and are used to treat a variety of diseases. These drugs are typically more complex and expensive to produce than traditional small-molecule drugs. The biologic market is highly competitive, with many companies vying for market share.
The biologic market is divided into two main segments: therapeutic biologics and biosimilars. Therapeutic biologics are drugs that are developed to treat a specific disease or condition, while biosimilars are drugs that are similar to existing biologic drugs but are not identical.
Some of the major players in the biologic market include Amgen, Biogen, Celgene, Gilead Sciences, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development, production, and marketing of biologic drugs. Show Less Read more